In this issue:
Oral bisphosphonates and risk of atypical fractures
Denosumab reduces new fractures in high-risk postmenopausal women
Paracetamol use, fractures and BMD
SC denosumab preferred over oral alendronate
Hip structure analysis of bisphosphonate users
Strontium reduces fracture risk in postmenopausal osteoporosis
Vitamin D guidelines
Denosumab improves bone strength: preclinical data
Sclerostin inhibits bone formation
Please login below to download this issue (PDF)